| Basics |
GlycoMimetics, Inc.
GlycoMimetics Inc is a clinical stage biotechnology company. It is engaged in discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.
|
| IPO Date: |
January 10, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$16.95M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.19 | 3.31%
|
| Avg Daily Range (30 D): |
$0.01 | 4.91%
|
| Avg Daily Range (90 D): |
$0.01 | 5.42%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.79M |
| Avg Daily Volume (30 D): |
.36M |
| Avg Daily Volume (90 D): |
.91M |
| Trade Size |
| Avg Trade Size (Sh.): |
350 |
| Avg Trade Size (Sh.) (30 D): |
738 |
| Avg Trade Size (Sh.) (90 D): |
585 |
| Institutional Trades |
| Total Inst.Trades: |
330 |
| Avg Inst. Trade: |
$1.69M |
| Avg Inst. Trade (30 D): |
$.59M |
| Avg Inst. Trade (90 D): |
$.59M |
| Avg Inst. Trade Volume: |
.22M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.96M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
182.44K |
|
|
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$-.59
|
$-.11
|
$-.59
|
|
Diluted EPS
|
$-.59
|
$-.11
|
$-.59
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -37.88M
|
$ -7.22M
|
$ -37.88M
|
|
Operating Income / Loss
|
$ -40.04M
|
$ -7.33M
|
$ -40.04M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -31.07M
|
$ -3.67M
|
$ -31.07M
|
|
PE Ratio
|
|
|
|
|
